Food | Page 165 of 210 | SpiritIndia.com

Smoking :: Nabi biopharmaceuticals completes enrollment in nicvax phase iib ‘proof-of-concept’ clinical trial

Nabi Biopharmaceuticals (Nasdaq: NABI) today announced it has completed enrollment for its Phase IIB “proof-of-concept” study for NicVAX(R) (Nicotine Conjugate Vaccine), the company’s novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. Enrollment for the trial was completed three months earlier than anticipated, paving the way for the release of trial results early in the second quarter of 2007.

Brain Cancer :: Peregrine receives regulatory approval for Cotara brain cancer clinical trial

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage products for the treatment of cancer and hepatitis C virus infection, today announced that it has received regulatory approval in India for a new clinical trial of its lead tumor necrosis therapy (TNT) agent Cotara(R). The trial is designed to test the safety and efficacy of Cotara in patients with glioblastoma multiforme, a deadly form of brain cancer. Cotara is currently being studied in a multi-center U.S. glioblastoma trial. Previous studies using Cotara to treat brain cancer have produced encouraging results, and Peregrine expects that positive data from this trial in combination with data from the ongoing U.S. clinical trial should provide the foundation for planning the future development and commercialization of Cotara.

Obesity :: Manhattan pharmaceuticals – oral oleoyl-estrone clinical program to include morbidly obese

Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US Phase 2a clinical trial evaluating oral OE in morbidly obese male subjects will be initiated in October 2006. The morbidly obese population in the US is estimated to be 14 million people. OE is the Company’s orally administered product candidate in development for the treatment of obesity.

Autism :: Risperdal for treatment of irritability associated with autistic disorder

The U.S. Food and Drug Administration (FDA) approved a new use of one of the leading prescription antipsychotic medications, RISPERDAL(R) (risperidone), for the treatment of irritability associated with autistic disorder, including symptoms of aggression, deliberate self-injury, temper tantrums, and quickly changing moods, in children and adolescents aged 5 to 16 years.(1) This is the first time the FDA has approved any medication for use in children and adolescents with autism.

ADHD :: NRP104 (lisdexamfetamine dimesylate) for the treatment of adhd

Shire plc announced that its collaborative partner New River Pharmaceuticals Inc. (Nasdaq: NRPH) has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NRP104 (lisdexamfetamine dimesylate), for the treatment of pediatric Attention-Deficit/Hyperactivity Disorder (ADHD).

Nutrition :: Researchers look to solve mystery behind egcg and probiotics

When talking about nutrition, EGCG and probiotics are two words that we’ve been hearing a lot about these days. But most consumers don’t know what they are, where they are found and what they do. Some of that mystery was cleared up this week at the 47th Annual Symposia of the American College of Nutrition (ACN) where leading nutrition experts revealed new research about the health benefits of these two ingredients.

Arthritis :: Trigosamine Jointcare Supplement, Maximum Strength Caplets

Maximum Strength Jointcare: A scientifically – advanced, once-a-day formulation that not only helps build and maintain healthy joints and cartilage, but also helps relieve joint discomfort. The new, improved formula offers smooth, steady, extended release of three powerful compounds for all day joint comfort.

Smoking :: Pfizer’s anti-smoking pill Champix approved in europe

Pfizer Inc said today that the European Commission has approved Champix(R) (varenicline), a novel pill for smoking cessation in adults. In addition, because smokers often need considerable support to quit successfully, Champix will be available with a patient support plan which smokers can customize to address their individual behavioral triggers as they try to quit smoking.

Lymphoma :: New indications for rituxan in patients with non-hodgkin’s lymphoma

Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved, after a Priority Review, two additional uses for Rituxan(R) (Rituximab) for patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL). One new indication for Rituxan is for first-line treatment of previously-untreated patients with follicular NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. The second new indication is for the treatment of low-grade NHL in patients with stable disease or who achieve a partial or complete response following first-line treatment with CVP chemotherapy.

Schizophrenia :: Paliperidone ER for the treatment of schizophrenia

Johnson & Johnson Pharmaceutical Research & Development (JJPRD), L.L.C. announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding a New Drug Application (NDA) for paliperidone extended-release (ER) tablets for the treatment of schizophrenia.